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Abstract
Introduction Being the most common primary brain tumor, glioblastoma presents as an extremely challenging malignancy
to treat with dismal outcomes despite treatment. Varying molecular epidemiology of glioblastoma between patients and intratumoral heterogeneity explains the failure of current one-size-fits-all treatment modalities. Radiomics uses machine learning
to identify salient features of the tumor on brain imaging and promises patient-specific management in glioblastoma patients.
Methods We performed a comprehensive review of the available literature on studies investigating the role of radiomics
and radiogenomics models for the diagnosis, stratification, prognostication as well as treatment planning and monitoring
of glioblastoma.
Results Classifiers based on a combination of various MRI sequences, genetic information and clinical data can predict noninvasive tumor diagnosis, overall survival and treatment response with reasonable accuracy. However, the use of radiomics
for glioblastoma treatment remains in infancy as larger sample sizes, standardized image acquisition and data extraction
techniques are needed to develop machine learning models that can be translated effectively into clinical practice.
Conclusion Radiomics has the potential to transform the scope of glioblastoma management through personalized medicine.
Keywords Glioblastoma · Neuro-oncology · Radiomics · Radiogenomics · Primary brain tumor

Glioblastoma
Glioblastoma has an incidence of 3.22 per 100,000 and
median overall survival (OS) of 14.6 months following standard treatment, which includes a combination of

surgical resection, radiation therapy and chemotherapy [1].
This “one-size-fits-all” model for the treatment of glioblastoma is now being questioned following research on various
pathways implied in intratumoral heterogeneity, arising as
a result of genetic and epigenetic makeup, levels of protein
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expression, metabolic or bioenergetic behavior, microenvironment biochemistry and structural composition [2]. Consequently, features differ on histopathology and imaging
across patients as well as spatially throughout a single tumor
[3–5]. Personalized treatment protocols targeting individual
patients’ tumor characteristics are thus being increasingly
advocated for improved success rates in glioblastoma management [4, 6, 7].

Radiomics and radiogenomics
Radiomics is an emerging application of neuroimaging
where advanced computational methods are used to quantitatively extract characteristics from clinical images that are
too complex for a human eye to appreciate [8, 9]. These
imaging characteristics, called “features” reflect tumor characteristics and inner organization as well as the tumor microenvironment [9]. Radiomics is a multi-step process including
the acquisition and preprocessing of images, segmentation,
feature extraction and selection, and advanced statistics
using machine learning (ML) algorithms (Fig. 1). The pipeline of radiomics is highly collaborative and involves contributions from clinicians, molecular biologists, statisticians,
and bioengineers [8].

IMAGE ACQUISITION

IMAGE
SEGMENTATION

Radiomics-derived imaging phenotypes are associated
with molecular markers to create ‘radiogenomics’ models
[5]. It is a rapid and reproducible tool to evaluate tumor
subtype, mutation status and intratumoral heterogeneity;
and non-invasively predicts tumor progression, survival
and response to targeted therapies using these characteristics [5, 8]. Radiogenomics offers more information as
opposed to surgical biopsy in view of spatial tumor heterogeneity [8], especially useful for genomic profiling in
recurrent glioblastoma which is driven by different clonal
populations with varying hypermutations and evasion
mechanisms [10]. Thus, clinical decision support systems
using radiomics will form the base for precision medicine
[9].

Applications of radiomics in glioblastoma
management
Radiomics analysis has been widely studied for its use in
subtyping brain tumors, predicting prognosis and treatment
planning, supporting its potential use as a biomarker. Combining radiomics analysis with clinical and genetic information can remarkably enhance the utility of these models.
PHENOTYPIC FEATURES
EXTRACTION AND
SELECTION FROM
IMAGING

RADIOMICS
ANALYSIS

MRI/CT/PET
images

Predictive Modelling
ROI labelling
Standardization of
acquired images
Performance Testing

SVM
LASSO Regression
Random Forest

Fig. 1  Pipeline showing radiomics workflow. Acquired clinical
images are subjected to standardization and segmentation to extract
Regions Of Interest (ROI). After selecting relevant features, advanced
statistical analysis is performed to classify and correlate radiomic features. (Images taken from these sources: Image acquisition—https://
www.mdpi.com/2072-6694/11/8/1148. Segmentation—https://www.
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Diagnosis and classification of glioblastoma
Simple features on structural MRI such as tumor size, location and enhancement patterns have been used to predict
histopathological subtypes of glioblastoma. Extracting complex features using image-processing software and combining with advanced MRI modalities can further improve the
accuracy of these models (Table 1).
Tumor location
It is well known that the location of the tumor affects the
outcomes in patients with glioblastoma. A “probabilistic
radiographic atlas” of more than 500 glioblastoma patients
showed associations between stereospecific frequency of
tumor occurrence with age, extent of resection, genetic
expression, and survival data. Interestingly, regions closer
to subventricular zone were seen to have MGMT unmethylated, mesenchymal, and EGFR-amplified tumors [17],
supporting their invasive nature and poor prognosis [38].
Another study showed correlation of tumor phenotypes with
their spatial distribution [30]. A comparison between solitary and multicentric glioblastoma revealed upregulation of
genes responsible for tumor cell motility and invasiveness
and poor prognosis in the multicentric radiophenotype [22].
Thus, tumor location and multicentricity can give important
clues to the cell of origin and tumor behavior.
Tumor size and contrast enhancement patterns
The correlation between tumor sizes and volume of different
components (enhancing, necrosis and edema) is well established [27]. Previously, ‘VASARI’, a semi-quantitative feature set including tumor volumes, was employed to predict
tumor subtypes and survival [15, 39]. In the VAK classification, a scoring system was developed to create phenotypes
using tumor volumetry in combination with age and KPS
annotation (Fig. 2) [35]. Volumetry was incorporated in a
radiogenomics model where it was combined with DNA
microarray analysis to train classifiers that can predict geneexpression patterns and survival. They showed that a high
ratio of contrast-enhancing volume to the necrotic tumor
volume (C:N) could predict overexpression of EGFR, an
important therapeutic target [40]. In another radiogenomic
study based on The Cancer Genome Atlas (TCGA) data,
stratification into high and low FLAIR radiophenotypes
reflected underlying edema and cellular invasion in glioblastoma, as they were associated with genes and microRNAs involved in cancer and cellular migration [36]. MRI
volumetric features are predictive of several cancer-relevant,
drug-targetable DNA mutations in glioblastoma. TP53, RB1,
NF1, EGFR, and PDGFRA mutations could each be significantly predicted by at least one imaging feature [18]. These
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studies provide a basis for genomic profiling and non-invasively selecting patients for personalized therapies using
tumor volumetry.
Radiomics can be used to distinguish solitary brain
metastasis from glioblastoma on structural MRI. Artzi et al.
developed an excellent classifier (AUC 0.96) with support
vector machine (SVM) using post-contrast T1 weighted
(T1CE) MRI. However, performance decreased when subtypes of brain metastasis were attempted to classify [11]. In
another study, contrast-enhancing and peritumoral hyperintense masks in T2-weighted (T2W) MRI-based deep
learning model showed best performance (area under curve
AUC 0.956) compared to the traditional machine learning
model (AUC 0.890) and human readers (AUC 0.774) [12].
However, when Shin et al. utilized both T1CE and T2W
sequences to develop a 2D CNN, they only achieved reasonable accuracy implying no clear benefit of combining the
two modalities [37].
Texture
Texture is a chief radiomic feature utilized for glioblastoma
phenotyping. In one study, a gray-level co-occurrence matrix
(GLCM) approach was employed for extracting phenotypic
texture features for necrosis, active tumor, and edema on
structural MRI. Features were significant predictors (p
value < 0.01) of prognosis but in areas of active tumor only
[41]. Another study was able to predict MGMT methylation
status using space-frequency texture analysis based on the
S-transform in T2W MRI, albeit with an accuracy of 71%,
requiring better algorithms [16]. Other studies based on texture features were able to predict MGMT methylation status
with reasonable accuracy [21, 20].
Occasionally, high‐grade gliomas (WHO Grade III and
glioblastoma) may have the same MRI appearance as lowgrade gliomas. Classifiers using texture along with size,
shape, intensity, and histogram features can be used to differentiate low-grade from high-grade gliomas. Performance
of these classifiers varies with the algorithm used, the best
performance was observed with SVM (AUC 0.932) and
Random forest (AUC 0.921) [28, 14].
Advanced MRI sequences and multimodal analyses
Advanced sequences such as Diffusion and Perfusion MRI
have been extensively used in brain tumors to evaluate
invasiveness, angiogenesis, and tumor behavior. Raw tumor
features from structural MRI and delta-radiomic features
from dynamic susceptibility contrast (DSC) perfusion MRI
were extracted to differentiate low-grade gliomas from highgrade gliomas. This classifier reached an AUC of 0.94 [19].
However, a Cochrane meta-analysis on 7 studies to differentiate untreated solid and non‐enhancing low-grade from
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2018 High grade and low grade gliomas,
BraTS 2017 (285)
2014 Treatmentnaïve glioblastoma, TCIA
(104)
2010 Newly diagnosed GBM (59)
2013 de novo glioblastoma (507)

Cho et al. [14]

2012 Newly diagnosed glioblastoma Upfront bevacizumab -treated (38)
2018 de novo glioblastoma (261)

Nakamoto et al. [28]

Pope et al. [29]

Rathore et al. [30]

2019 Grade III and IV glioma (224)

Naeini et al. [27]

2018 Glioblastoma (133 training, 60 validation cohort) (193)
2017 8 PCNSL and 36 glioblastoma (44)

2018 54 PCNSL and 23 atypical glioblastoma (77)
2013 Glioblastoma (46)

Suh et al. [26]

Lin et al. [25]

Li et al. [24]

Kong et al. [22]
Lee et al. [23]

Korfiatis P et al. [21]

Hajianfar G et al. [20]

Gutman et al. [18]
Jeong et al. [19]

Drabycz et al. [16]
Ellingson et al. [17]

Colen et al. [15]

2015 Glioblastoma, TCIA (76)
2019 High-grade and lowgrade gliomas
(25)
2019 Glioblastoma with known MGMT
methylation status (82)
2016 Glioblastoma with known MGMT
methylation status (155)
2016 Treatmentnaïve GBM (51)
2019 newly diagnosed GBM (123)

2012 newly diagnosed glioblastoma (51)

Barajas Jr et al. [13]
Random forest

Mixed effect models

Deep learning

Support vector machine

Machine learning algorithm

Tumor stratification (gene expression
in high-versus-low ADC tumors)
Imaging based phenotypes for riskstratification

Differentiation of glioblastoma and
primary CNS lymphoma
Differentiation of glioblastoma and
primary CNS lymphoma
Associating imaging features with
mesenchymal subtype
Glioma grading

Predicting MGMT methylation status

Phenotyping multicentric GBM
Predicting IDH1 mutation status

Predicting MGMT methylation status

Predicting MGMT methylation status

Predicting MGMT methylation status
Probabilistic radiographic atlases
(tumor locations indicative of cells
of origin)
Predicting somatic mutations
Glioma grading

Positive Pixel Count and Nuclear
Algorithms
Support vector machine

Random forest

Quantitative volumetric analysis

Random forest

Histogram analysis

Random forest

Shortest path algorithm
–

Support vector machine

Decision Tree classifier

Random forest

Bicubic interpolating kernel
Mutual information algorithm/
ADIFFI analysis

Radiogenomics in invasive phenotype Robust multi-array (RMA)

Differentiation between glioblastoma
and brain metastasis
Distinguishing glioblastoma from
single brain metastasis
Histopathologic correlation of MRI
features
Glioma grading

2019 Glioblastoma and brain metastasis
(439)
2020 Glioblastoma and metastases (248)

Artzi et al. [11]

Bae et al. [12]

Task

Authors and reference no Year Study sample (n)

Table 1  Application of radiomics in glioblastoma diagnosis and classification

Accuracy 80.19% within subtypes,
73.58% across all patients

Mean AUC 0.921 of the radiomics
classifier
Volume of contrast enhancement: AUC
0.78 central necrosis: AUC = 0.73
Accuracy 0.806, sensitivity 0.822,
specificity 0.773, AUC 0.800

Prediction rate 70.3%-87.3%, accuracy
66.3%83.4% in the external validation set
AUC = 0.88, accuracy = 80% Radiomics model
AUC 0.83 for mean ADC

AUC 0.85, sensitivity 0.803, specificity 0.81

AUC 0.646—0.722
Accuracy 0.950 HG and 0.850 for LG;
AUC 0.94
AUC 0.78

Accuracy 71%

AUC 0.9213

Accuracy 0.85, sensitivity 0.86, specificity 0.85, AUC 0.96
AUC 0.956, sensitivity 90.6%, specificity 88.0%, and accuracy 89.0%

Performance parameter
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2018 Glioblastoma with known MGMT
methylation status (98)
2017 High grade and low grade gliomas
(120)
2012 Glioblastoma, TCIA (142)
2011 Glioblastoma, TCIA (78)

Xi et al. [33]

Shin et al. [37]

Zinn et al. [35]
Zinn et al. [36]

2021 Glioblastomaand solitary brain
metasasis patients (598)

2018 GBM patients (98)

Xi et al. [33]

Zhang et al. [34]

2018 Grades II, III, and IV gliomas (153)

Tian et al. [32]

Support vector machine

Support vector machine

Support vector machine

Support vector machine

LASSO

Machine learning algorithm

Patients stratification
Radiogenomic mapping of edema/cel- Ingenuity pathway analysis (IPA)
lular invasion
Differentiation of glioblastoma from Deep learning
solitary brain metastasis

Glioma grading

Predicting MGMT methylation status

Predicting MGMT methylation status

Glioma grading

2019 Newly diagnosed GBM patients (201) Predicting MGMT status

Task

Sasaki et al. [31]

Authors and reference no Year Study sample (n)

Table 1  (continued)

Accuracy 89%, AUC 0.889

Accuracy 67%, Sensitivity 67%, Specificity 66%, Positive predictive value
67%, Negative predictive value 67%,
Prevalence of pMGMT methylation
50%
Accuracy 96.8%, AUC 0.987 LGGs vs
HGGs; accuracy 98.1%, AUC 0.992
for grades III vs IV
Training: accuracy 86.59% validation:
accuracy 80%
Training: accuracy 86.59%, validation:
accuracy of 80%
Accuracy 0.945

Performance parameter
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Fig. 2  Volume, Age, KPS (VAK) classification and phenotype. Volume, Age, KPS (VAK)-A and B classes showing (A) Kaplan Meier
survival plot (B) representative MRI images for VAK-A and VAK-B
patients and (C) VAK-A and VAK-B survival validation in an independent patient set (N = 64) and (D) combination of the discovery and

validation set (N = 142) for patient with full VAK annotation including the Proportional Hazards Model correcting for Age and KPS.
(Source https://journals.plos.org/plosone/article?id=10.1371/journal.
pone.0041522)

high-grade gliomas using DSC MRI features (rCBV and
Ktrans) reported wide range of estimates for both sensitivity
and specificity, making these parameters less reliable [42].
Diffusion MRI was employed to compare the expression
of various genes between the high- versus low- Apparent
Diffusion Coefficient (ADC) tumors in a subset of patients.
High-ADC tumors were found to have higher expression of
13 genes, 6 of which encode for extracellular matrix (ECM)
molecules including collagen or collagen-binding proteins,
suggesting a role of these genes in pro-invasive phenotype
[29]. In another study, physiologic MRI was correlated with
stereotactic image-guided biopsies to differentiate contrastenhancing and nonenhancing tumor areas. DSC MRI was
useful for identifying tissue specimens with higher tumor
proliferation, necrosis, and vascular hyperplasia in the contrast-enhancing component of the lesion, while diffusion
MRI may be useful to detect infiltrating tumors in the nonenhancing region. This is of particular interest for defining

tumor burden in non-enhancing regions, where distinguishing reactive edema from biologically active infiltrative tumor
is clinically important. In this study, accuracy of the results
could be confounded by the misregistration arising as a
result of brain shift [13].
MR imaging features of Primary CNS Lymphoma
(PCNSL) and glioblastoma overlap, with differing survival
outcomes and treatment options. In a study where perfusion
and diffusion-weighted MRI were used to differentiate glioblastoma from lymphoma, mean ADC and plasma volume
(rVp) were higher in the glioblastoma compared to PCNSL.
Moreover, mean ADC was superior (AUC 0.83) to rVp and
permeability transfer constant (Ktrans). This was true for
contrast-enhancing regions only, possibly due to increases in
tumor cellularity, microvascular permeability, and vascular
proliferation [25]. In another study, ADC was outperformed
by a multi-parametric (T1WCE, post-contrast T2W and
FLAIR) and multiregional radiomics classifier with AUC
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0.921 [26]. This questions the benefit of including advanced
sequences in classifier in the presence of conventional MRI.
Other studies have explored the utility of multiparametric MRI to create more accurate radiomic models for tumor
subtyping, grading and predicting mutational status. Rathore
et al. used 267 multiparametric MRI based radiomic features, extracted from T1-weighted (T1W), T2W, T1CE, T2
FLAIR, DSC, and DTI to subtype de novo glioblastoma into
three imaging phenotypes. For example, the solid subtype
was characterized by highly uniform vascularization, highest
cell densities, small-sized edema, moderately spherical and
well-circumscribed appearance, with peritumoral edematous tissue having signs of heterogeneous neovascularization. This subtype had a predilection for the right temporal
lobe and was associated with the worst prognosis. A personalized treatment regimen would involve very aggressive
peritumoral resection and radiation dose escalation in these
tumors [30]. Combining various MRI sequences can also
improve classifier accuracy for tumor grading [32, 34]. Classifier performance also increased using MRI features from
multiregional and multiparametric structural MRI to predict
MGMT methylation status in glioblastoma [33, 24]. Similarly, IDH 1 mutation status was predicted using radiomic
features on multiparametric MRI with enhanced accuracy
when age and multiple regions were included [23].

Prognostication of glioblastoma
It is increasingly important for physicians to understand
an individual patient’s prognosis and adjust their therapy
accordingly. For this reason, a large number of studies aimed
to predict outcomes using radiomics alone and augmented
with clinical data, genomics, and proteomics can be used.
(Table 2).
Conventional MRI features
Studies have used various features extracted from conventional MRI to predict patient outcomes in glioblastoma.
Longer median survival was associated with higher sphericity, surface-to-volume ratio and edge enhancement of
glioblastoma lesions on T1W MRI [54]. Lao et. al divided
features into ‘handcrafted features’ and ‘deep features’ to
create a feature signature, which when coupled with clinical
risk factors such as age and Karnofsky Performance Score,
was able to predict overall survival (OS). Compared with
the predictive ability of traditional risk factors, the proposed feature signature achieved a superior prediction of OS
(C-index = 0.739) [49]. Similar combined models reached
C-index of 0.974 [56].
Texture, tumor shape and volumetric features were
extracted, and combined with age to produce a model that
would predict short-term, mid-term, and long-term OS
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[56, 53]. Zhou et al. went one step further and identified
spatial-based characteristics from tumor sub-regions that
can be used to predict survival time in patients [57]. Similarly, Chaddad et al. found three texture features extracted
from active part of the tumors that significantly predicted
survival outcomes compared to the necrotic and edematous
parts [41]. Moreover, these radiomic models could predict
survival in different molecular subtypes as well [55]. Addition of location-based features of brain tumors to radiomic
features extracted from conventional MRI enhanced the
ability of a model to predict OS of patients by 9%. Furthermore, classifying groups according to resection status
can also increase the accuracy of such prediction models
[58]. Verma et al. used MRI features to create a radiomics
risk score for predicting PFS. With a concordance index of
0.80, these features also correlated well with histopathologic
attributes associated with glioblastoma aggressiveness. Such
scores can be easily utilized in clinical settings [59].
Advanced MRI features
Advanced MRI modalities have also been also explored to
predict glioblastoma patient outcomes [52]. It was seen that
high rCBV in the non-enhancing region of tumor was predictive of worsening OS and Progression-free Survival (PFS)
[48]. ADC histogram analysis was useful to predict PFS
in newly diagnosed as well as recurrent glioblastoma [29,
60]. In these studies, low ADC predicted poor outcomes.
Models incorporating both conventional and advanced MRI
sequences may show better performance at predicting the
prognosis.
Radiogenomics and proteomics
MGMT promoter hypermethylation is associated with better
prognosis and response to therapy. This mutational status
alongwith IDH has been combined with radiomic features
from structural MRI to stratify patients based on overall
survival producing more robust radiomics-based prognostic
models [44, 51]. Zinn et al. stratified VAK annotated cases
further with molecular signatures and found a 10.5 months’
additional survival benefit for the group with MGMT promoter methylation [15]. In another study, glioblastomas
were first divided into groups based on vascularization
(rCBV values). It was seen that MGMT methylation was
a positive predictive factor for OS (p = 0.003, AUC = 0.70)
in the moderately vascularized tumors. However, there was
no significant effect of MGMT methylation in the highly
vascularized tumors (p = 0.10, AUC = 0.56) [45]. Contrastingly, some studies did not find any significant association of
prognosis with MGMT promoter hypermethylation [54, 31].
This could be due to insufficient feature selection methods.
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2020 Glioblastoma (120)

2016 Glioblastoma, TCIA (40)

2008 Glioblastoma (25)

2021 NCT034393 32 clinical study (96)
2013 Glioblastoma, TCIA (75)

2020 Glioblastoma (116)

2016 Newly diagnosed glioblastoma (181)

2014 GBM (45)

2017 Glioblastoma (112)

2019 Glioblastoma, TCIA (137)

2017 Supratentori al GBM initiated TMZbased concurrent chemothera py

2020 Newly diagnosed glioblastoma (216)

2018 GBM patients from the BraTS 2017
dataset (163)
2019 Newly diagnosed GBM (201)

2019 GBM (159)
2015 De novo GBM (82)
2019 GBM (105)

2017 Glioblastoma (54)

2021 BraTS 2019 data

Choi et al. [44]

Chaddad et al. [41]

Diehn et al. [40]

Fuster-Garcia et al. [45]
Gutman et al. [39]

Hsu et al. [46]

Kickingered er et al. [47]

Jain et al. [48]

Lao et al. [49]

Liao et al. [50]

Molitoris et al. [51]

Park et al. [52]

Sanghani et al. [53]

Tixier et al. [54]
Yang et al. [55]
Zhang et al. [56]

Zhou et al. [57]

Soltani M et al. [58]

Sasaki et al. [31]

Radiomics features + expression profile of 21 hypoxiaassociated genes
Radiomics + Clinical + MGMT and
IDH-1 status
Radiomics

2018 Glioblastoma (115)

Beig et al. [43]

Pre-trained CNN via transfer learning/ deep learning
Gradient boosting decision tree

Random forest and information gain

Cox regression

Random forest and information gain

Cox regression
Cox regression

Two-step algorithm

Decision trees (DT)

Deep learning/CNN

Random forest and information gain

Machine learning algorithm

Image‐based spatial characteristics in Support vector machine
tumor subregions
Predicting survival using location
Linear, regression, random vector
based features
forest, support regression

Cox regression
Age, gender, MGMT status, performance status, resection extent, race,
tumor site
Cox regression
Multiparametric MR prognostic
model (radiomics score + clinical
predictors)
Radiomics
Support vector machine classificatio
n
Radiomics + MGMT status
Supervised principal component
analysis (SPCA)
Radiomics + MGMT status
–
Radiomics
Random forest
Radiomics + clinical
Logistic regression

Radiomics (predictive of geneexpression patterns)

Clinical + genomic biomarkers + imaging of the nonenhancing
component
Radiomics features + clinical factors

Radiomics (predictive of geneexpression pattern)
MGMT methylation and rCBV
Radiomics (predictive of molecular
profile)
Radiomics features predictive of
Immunophenotypes
Radiomics + Clinical + Molecular

Predictors of survival

Authors and reference nos Year Study sample (n)

Table 2  Application of radiomics in glioblastoma survival prediction

AUC 0.69 for 12 month survival status
Training: C index, 0.971, validation:
C-index 0.974
Accuracy 87.50% (dataset 1) 86.36%
(dataset 2)

Accuracy 97.5%

C-index 0.74

Accuracy 0.81, AUC of the short and
long survival time class 0.79 and
0.81
–

Combined model Cindex = 0.739

Prediction error reduced by 36% for
PFS and 37% for OS
Joint imaging and clinical model AUC
0.69

Accuracy 79%

AUC 0.70 for MGMT
–

Combined Cindex = 0.69 training set,
0.83 on validation set
Combined overall and progression-free
survival AUC 0.73 and 0.67
Accuracy 79.31, sensitivity 91.67, and
specificity 98.75%
–

Performance parameter
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Concordanc e index 0.80
LASSO, Cox regression
Verma R et al. [59]

2020 Glioblastom a patients (156)

Assessingfeatures that are prognostic
for progression-free survival

Performance parameter
Authors and reference nos Year Study sample (n)

Table 2  (continued)

Predictors of survival

Machine learning algorithm

Journal of Neuro-Oncology (2022) 156:217–231
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Integrative models promise a reduction in prediction
errors [44, 43]. Chaddad et al. created multi-omic integrative model using radiomic, clinical, protein expression and
genetic features to predict the outcome for IDH1 wild-type
glioblastoma patients which reached AUC of 78.24% [61].
Liao et al. extracted First order and multi-dimensional features from segmented lesions on FLAIR MRI and gave a
feature importance score for feature selection [50]. When
combined with genetic expression, the Gradient Boosting
Decision Tree model predicted both short-term and longterm survival with an accuracy of 0.81. While six metagenes
showed significant interactive effects with image features,
this study was limited by unavailability of complete genomic
data [50].
Immunophenotypes in glioblastoma are important as they
predict response to immunotherapy and outcomes. Hsu et al.
used radiomic immunophenotyping models to predict patient
prognosis [62]. They showed that the phenotype with the
worst prognosis comprised highly enriched myeloid-derived
suppressor cells and lowly enriched Cytotoxic T lymphocytes [62].

Treatment of glioblastoma
Studies have shown the benefit of radiomics analysis in planning surgical procedures, evaluating the dose of radiotherapy, predicting the effective dose of chemotherapeutic agents
and stratifying patients who will benefit from therapy. After
initiating therapies, radiomics can be used to differentiate
mimicking entities like true progression, pseudoprogression
and radionecrosis(Table 3).
Surgical resection
A study correlating tumor surface regularity on T1W MRI
with OS of 165 glioblastoma patients who underwent surgical resection highlighted that patients with surface-regular
tumors had a higher survival rate and benefit from total
tumor resection as compared to surface-irregular tumor
patients [62]. Gaw et al. created a hybrid model to predict
tumor cell invasion preoperatively for more effective surgery and radiation planning. The hybrid model, comprising
an ML component that was driven by imaging data and a
mechanistic model of tumor growth called the ProliferationInvasion (PI) model, outperformed the individual components [68]. Thus, radiomics can help plan a targeted and
personalized surgical treatment.
Radiation therapy (RT) planning
Radiomics shows immense potential to guide precision
radiotherapy. Prediction models can estimate the extent of
tumor infiltration and can help identify areas that are at a
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2021 Pre-radiotherapy scans (35)
2019 Glioblastoma patients (76)

2020 Patients receiving bevacizum ab
(149)

2019 gbm patients (98)

2019 Primary GBM patients (18)

2017 Multicenter BRAIN trial (291)

2016 Patients recurrent glioblastom a prior
to bevacizum ab treatment (172)

2019 Glioblastom as within 3 months after
standard Treatment (61)
2018 Glioblastom a, TCIA (116)

Baine et al. [64]
Bani-Sadr et al. [65]

Cai et al. [66]

Elshafeey et al. [67]

Gaw et al. [68]

Grossmann et al. [69]

Kickingereder et al. [47]

Kim et al. [70]

Rathore et al. [76]

Patel et al. [75]

Zhang et al. [74]

Yoon et al. [73]

Yan et al. [72]

Pope et al. [60]

Petrova et al. [71]

Pérez-Beteta et al. [62]

Predict subsequent location of recurrence
Predicting Risk of Pseudoprogression
Differentiate pseudoprogression from
early progression
Predicting the response to bevacizumab in brain necrosis after
radiotherapy
Differentiating between pseudoprogression and progressive disease
Variation in cell density

2016 Glioblastoma (65)

Akbari et al. [63]

Supervised principal component
(superpc) analysis

Graphbased semisupervised learning
algorithm

Support vector machine

Logistic regression analysis

–
Random forest

Support vector machine

Machine learning algorithm

2019 Patients with recurrent glioblastom
a (54)
2011 Up-front bevacizum ab-treated + con- Stratify survival in patients treated
with bevacizumab
trol patients with newly diagnosed
GBM (121)
2020 Newly diagnosed cerebral glioblasTo identify peritumoural progrestom a (57)
sion areas in patients treated with
surgery and concomitant chemoradiotherapy
2020 GBM patients (118)
Prediction of overall survival after
postoperative concurrent chemoradiotherapy
2018 Pathologically confirmed necrosis or Distinguishing radiation necrosis
progression (87)
from tumour progression after
gamma knife radiosurgery
2021 Glioblastoma patients (76)
Differentiate between early true progression and Pseudoprogression
2018 De novo glioblastoma a patients (90) Predicting recurrence of GBM by
estimating peritumoral edema
infiltration

Combined model Cindex 0.768, iAUC
0.790
Overall predictive accuracy 73.2%;
AUC 0.73

Deep learning/CNN
RUSBoost ensemble classifier

AUC 0.80, sensitivity specificity 78.2,
66.7%, accuracy 73.7%
Accuracy 87.51%, sensitivity 80.65%,
specificity 87.63%

Training: accuracy 92.6%; validation:
accuracy 78.5%. Multimodal MR
radiomics

Convolution al neural network

Machine learning-based tissue classification
Support vector machine

–

Radiomic superpc predictor (IBS and
iAUC of 0.095 and 0.792 for OS;
0.117 and 0.678 for PFS) was higher
External validation AUC 0.85; internal
Validation AUC 0.96
Discovery: C index 0.76; validation: C
index 0.74
Accuracy 0.78% (OS) 0.82% (PFS6)

Ktrans: AUC = 94%; rCBV:
AUC = 89.8%
Hybrid ML-PI model mean absolute
predicted error (MAPE) of 0.106
–

AUC 0.84, sensitivity 91%, specificity
93%
AUC 0.82
Combined model accuracy 79.2%,
specificity 75%
AUC 0.912

Performance parameter

–

Differentiate pseudoprogression from Generalized linear model
early tumor progression
Cox proportional hazards regression
Predicts survival and response to
surgery
analysis
Response to treatment
Support vector machine

Stratify survival and progression in
patients treated with bevacizumab
Stratify survival in patients treated
with bevacizumab

Task

Authors and reference nos Year Study sample (n)

Table 3  Application of radiomics in glioblastoma treatment
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higher risk of tumor recurrence for targeted RT [63, 76].
Rathore et al. worked on a method for estimating peritumoral edema infiltration using radiomics by testing on preand post-operative multimodal MRI sequences in 90 de novo
glioblastoma patients and found that recurrent tumor regions
revealed higher vascularity and cellularity when compared
with the non-recurrent regions [76]. A similar study done on
31 de novo glioblastoma patients confirmed these findings
and also highlighted the importance of using multiparametric pattern analysis methods for planning a focused treatment approach to decrease recurrence rate [63]. Radiomics
can guide in planning radiation therapy dose escalation in
areas with higher risk of tumor recurrence as well as increasing gross total resection. This method can also help prevent
dose-related toxicities seen with RT, salvaging the neural
tissue at lower risk areas from damage [77].
Chemotherapy with temozolomide (TMZ)
Chemotherapy with TMZ along with adjuvant RT increases
median OS [78]. However, TMZ resistance arises due to
tumor heterogeneity. Yan et al. confirmed the importance
of radiomics analysis in predicting disease progression in
57 glioblastoma patients treated with TMZ post-surgery
using structural, diffusion and perfusion MRI. The study
found lower ADC, higher FLAIR and hyperintense signals
on T1CE in areas with a higher risk of tumor progression
[72]. Another study assessed the efficacy of deep-learning
based survival-prediction in 118 patients undergoing concurrent chemoradiotherapy with temozolomide post-surgery
using features from multimodal MRI.. It highlighted that
both clinical and radiomic features should be used hand in
hand to predict OS of glioblastoma patients [73]. This reiterates the importance of radiomic models for identification of
suitable treatment regimens guided by predicted response.
Therapy with bevacizumab
Bevacizumab is a monoclonal antibody targeting vascular
endothelial growth factor (VEGF) used in patients with
recurrent glioblastoma. However, variations in genetic
makeup of VEGF among individuals can lead to resistance
to bevacizumab, limiting its use [47]. Radiomics analysis
can provide important biomarkers for selecting patients who
will benefit from this therapy. Pre-treatment T1W and T1CE
MRI of patients with recurrent glioblastoma were used to
develop radiomics-based predictors of survival and progression. This has utility as a low-cost instrument for identifying
treatment response in these patients [47, 69]. Using ADC
and CBV of 54 patients with recurrent glioblastoma that
were treated with RT and temozolomide, and subsequently
treated with bevacizumab, was effective in segregating
patients into responders and non-responders to bevacizumab
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treatment [71]. In a more complex model, a stratification
model was created which integrated the pre-treatment MRI
radiomics signature, the interval between radiotherapy and
diagnosis of brain necrosis, and the interval between diagnosis of brain necrosis and treatment with bevacizumab to predict which patients will benefit from bevacizumab therapy
for brain necrosis after radiotherapy. This model performed
well with an AUC of 0.912 in the validation set [66].
Evaluating response to radiation therapy (RT)
and chemotherapy
Radiotherapy can result in conditions that mimic true disease
progression. Texture features derived from enhancing component and perilesional edema on structural MRI were used
to differentiate pseudoprogression from true progression in
glioblastoma [79]. Another model displayed a boost in accuracy when MGMT status was incorporated [65]. While these
studies were based on post-RT MRI, pre-RT MRI scans may
also predict the development of future pseudoprogression
in glioblastoma patients [64]. Recent studies incorporated
diffusion and perfusion MRI which reflect hypercellularity and hypervascularity to classify pseudoprogression.the
accuracy is superior in these models than those based on
conventional MRI alone [70, 67, 80]. Another post-RT effect
that is difficult to differentiate from true progression is radiation necrosis. This can also be detected using ML classifiers
based on traditional and delta radiomic features derived from
MRI [74]. Pseudoprogression can also follow chemotherapy
and radiomics offers hope in this regard. A clinio-radiomic
classifier including multimodal MRI features was developed
which showed an AUC of 0.80 [75].

Challenges in the clinical application
of radiomics for glioblastoma
Despite the proven potential of radiomics in various aspects
of glioblastoma management, these methods are yet to be
introduced in mainstream clinical practice. Obstacles to
translation include limited reproducibility of algorithms and
less robust machine models. Formation of bodies to recommend standardization methods such as QIBA and QIN offer
hope [81, 82].

Data availability and sharing
The majority of the studies exploring radiomics in glioblastoma are limited by small sample sizes. Biological variability of the tumor among patients explains why radiomics is
still in its infancy. Promoting collaborative studies, sharing
of data across institutions and making more high-quality
datasets publicly available (such as Huiyihuiying Inc.,
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BraTS, TCGA [83–85]) will result in more robust as well
as reproducible models. This also requires overcoming the
administrative and regulatory barriers to large-scale data
sharing. In addition, clearly documenting the analysis and
making original codes and data available will allow other
investigators to replicate the results [62].

Image acquisition
The inclusion of retrospectively collected, multi-center
data for clinical trials on radiomics is limited by variations
across institutions in image acquisition such as the protocol defined by physicians, resolution, slice thickness, and
washout period for contrast imaging of the acquired images
[86]. Features extracted from MRI images can be influenced
by field of view, field strength and slice thickness [87]. To
combat the variability in the data collected, standardized
steps are recommended following the image acquisition like
intensity normalization, voxel re-slicing, use of a specific
anatomical plane for multiparametric data, standardization
of signal intensity prior to image listing, and developing
algorithms for multiple MR modalities for image registration [86, 88, 89].

Segmentation and feature extraction
Although considered the highest standard for segmentation, manual segmentation of images is labor-intensive and
increases risk of observer bias. In contrast, semi- and fullyautomated methods can improve robustness and reproducibility [90]. Extracted features are dependent on the segmented region and tumor margins therefore segmentation
is the key step [87]. While automated feature extraction has
lower degree of variation in the scoring of semantic features
[86], these methods can still lead to site-specific variations
when obtaining imaging [86].

Machine learning models
Accuracy of ML models is limited by overfitting and underfitting. Overfitting of data occurs when doing feature extraction on high-dimensional, large-scale data [83]. However, it
can be reduced by feature selection methods such as principal components analysis (PCA), sparse PCA, auto-encoders,
etc. [91, 92]. Underfitting, due to small sample sizes, can be
addressed using techniques like SMOTE [93].
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Conclusion
Radiomics offers revolutionary changes in the scope of glioblastoma management through facilitating a personalized
approach at various stages. Integrative models that include
clinical, genetic and other molecular data can enhance the
accuracy. The main limitation seen in most studies is the
small sample size and the retrospective nature of these projects. Besides, variability in methods to generate data across
institutions limits the generalizability in different patient
populations. Whilst the results of these studies are promising, a key goal moving forward is to make these models
more reproducible in a wide array of settings. Multicenter
clinical trials are needed to translate these models and provide actual benefits to glioblastoma patients.
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